Mandate

Vinge advises the founders of Future Media Group in conjunction with the sale to Caybon

Vinge has advised the founders Rikard Virta, Linus Wennerström and Johan Oscarsson as well as the other shareholders in conjunction with the sale of Future Media Group AB to Caybon.

Future Media Group specialises in helping media owners and growth companies to generate new revenue streams through business development, product development and sales. In close co-operation with its partners, new advertising formats, media solutions and marketing concepts are developed, and the solutions to the correct target groups are prepared in conjunction with the different sales organisations specialising in different types of products and customer segments.

Future Media Groups current partners currently include large media groups such as Bonnier and Stampen, as well as niche actors such as Preglife (the Nordic Region’s leading pregnancy app) and the digital veterinary service, Firstvet. The company has offices in Stockholm and Oslo and employs approximately 100 persons. 

Vinges team has primarily consisted of Jonas Johansson, Carl Sander, Ellinor Wargenbrant and Linus Adolfsson (M&A), as well as Sara Dahlros Sköld and Ellinore Boström Andersson (VDR).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026